CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 161 filers reported holding CLOVIS ONCOLOGY INC in Q3 2019. The put-call ratio across all filers is 1.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2019 | $551,000 | -18.0% | 140,226 | +210.4% | 0.01% | -47.4% |
Q2 2019 | $672,000 | -97.0% | 45,175 | -81.0% | 0.02% | -96.6% |
Q2 2017 | $22,249,000 | +15.4% | 237,631 | -21.5% | 0.55% | +17.9% |
Q1 2017 | $19,272,000 | +136.2% | 302,689 | +64.8% | 0.47% | +168.6% |
Q4 2016 | $8,160,000 | +31.3% | 183,693 | +171.9% | 0.18% | -40.1% |
Q3 2015 | $6,213,000 | – | 67,559 | – | 0.29% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |